Summary
Other Scenarios:
- GSK - NVS
- GSK - SNY
- NVS - ACAMY
- SNY - ACAMY
| Buyer: | GlaxoSmithKline plc (ADR) (GSK) | Last Price: | 45.33 | Market Cap.: | 122.74B |
|---|---|---|---|---|---|
| Target: | Acambis plc (ADR) (ACAMY) | Last Price: | 3.70 | Market Cap.: | 199.19M |
Lines of Business Summary:
- GlaxoSmithKline plc (ADR) (GSK) competes in 1 industry and 222 product/service groups
- Acambis plc (ADR) (ACAMY) competes in 1 industry and 4 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- GlaxoSmithKline plc (ADR) (GSK) has 17 and Acambis plc (ADR) (ACAMY) has 0 suppliers that rely on a material % of their business. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
893 |
Biopharmaceuticals |
|
|
366 |
|
Medical Devices |
|
241 | |
|
Nutritional Health |
|
25 | |
|
Outsourced Services |
|
66 | |
|
Scientific Products |
|
35 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 251)
|
Target (Total: 6)
|
Buyer
|
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 67)
|
Target (Total: 5)
|
Buyer (Total: 25)
|
Target (Total: 2)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 103,483 | 285 |
| Revenue Per Employee | 461,819.2 | 78,593.9 |
| Total Revenue | 11,914.9 | 5.5 |
| Total Expenses | 8,747.7 | -3.4 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
3,268.9 | 4.5 |
|
SG&A Expense
|
3,635.9 | 5.5 |
|
Research & Development
|
2,080.2 | 15.2 |
|
Other Operating Expense
|
-237.3 | -28.7 |
|
Operating Income
|
3,167.2 | 8.9 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
42.39 | 2.01 |
|
Fwd P/E
|
11.47 | n/a |
|
Fwd P/Rev
|
2.67 | n/a |
| Book Value | 19,152.8 | 125.6 |
|
Curr Portion of LTD/Cap Lease
|
0.0 | 0.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals > Infectious Diseases > Viral > Vaccines
Business Description
Buyer
GlaxoSmithKline plc (GSK) is a global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products. It has and operations in some 114 countries, with products sold in over 140 countries. The Company operates in two segments: Pharmaceuticals (prescription pharmaceuticals and vaccines), and Consumer Healthcare (over-the-counter medicines, oral care and nutritional healthcare). The markets for its products are the United States, France, Japan, United Kingdom, Italy, Germany and Spain.
Target
Acambis plc is a biopharmaceutical company operating in the infectious disease arena, with a focus on developing new vaccines. The Company supplied smallpox vaccines to more governments than any other company. To maximize the revenues from its smallpox franchise, the Company is now targeting two principal opportunities: ACAM2000 warm-base manufacturing for the United States Government and supply of MVA3000 to the United States Government. Warm-base manufacturing would produce doses of ACAM2000 each year for the Strategic National Stockpile. Together with its partner, Baxter International Inc., the Company is bidding for a major contract to supply the United States Government with doses of its MVA3000 attenuated smallpox vaccine. This vaccine is for the proportion of the population who could suffer adverse reactions to smallpox vaccines, such as ACAM2000. In October 2006, Acambis sold its Berna Products Corporation business to Crucell N.V.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
76.59 | 38.07 |
|
Operating Margin %
|
33.43 | -66.49 |
|
Quick Ratio
|
1.02 | 2.68 |
|
Current Ratio
|
1.32 | 2.88 |
|
Coverage Ratio
|
-0.02 | -0.06 |
| Total Assets | 61,834.1 | 165.7 |
| Return on Equity % | 55.3 | -40 |
| Return on Assets % | 17.13 | -30.31 |
|
Cash+ ST Inv. Per Share
|
3.69 | 1.66 |
| Total Debt | 21,083.4 | 18.2 |
| Total Debt to Equity % | 110.08 | 14.49 |
| Total Debt to Tangible Equity % | 279.88 | 18.29 |
|
Debt to Asset %
|
34.10 | 10.98 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Medical Devices |
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
Respiratory
The Respiratory Subsector includes medical devices that diagnose and treat respiratory diseases.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Scientific Products |
|
|
|
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
Upper Respiratory |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Acute Coronary Syndrome (ACS) |
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Recombinant B-Type Natriuretic Peptides (BNP)
Therapeutics that treat the ineffective pumping of the heart by increasing the excretion of sodium and water in urine.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat the ineffective pumping of the heart by preventing the entry of sodium or potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Primary Pulmonary Hypertension |
|
|
|
Prostacyclins
Therapeutics that relieve pulmonary hypertension by causing vasodilation of the pulmonary blood vessels.
Buyer Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Lesion/Scaling Disorders |
|
|
|
Dermatitis |
|
|
|
Atopic (Eczema) |
|
|
|
Immunomodulators
Therapeutics that treat atopic dermatitis by inhibiting T-lymphocyte activation.
Buyer Products:
|
|
|
|
Seborrheic (Dandruff) |
|
|
|
Coal Tar
A coal byproducts used in the treatment of various skin disorders.
Buyer Products:
|
|
|
|
Diaper Rash |
|
|
|
Zinc Oxide
Therapeutics that treat diaper rash by forming a protective barrier against the skin.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that treat psoriasis by stimulating immune response and regulating inflammation and skin cell proliferation.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastric |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Abdominal Gas |
|
|
|
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.
Buyer Products:
|
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Neurokinin-1 (NK-1) Receptor Antagonists
Therapeutics that prevent or treat nausea and vomiting by inhibiting the neurotransmitter NK-1 (Substance P) from binding to its receptors.
Buyer Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Hepatitis |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat hepatitis by inhibiting the action of reverse transcriptase, an enzyme necessary for DNA synthesis using an RNA template.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides/Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that control high blood sugar by stimulating the release of insulin as well as sensitizing organs to insulin.
Buyer Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)/PPAR Agonists
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin and sensitizing organs to insulin.
Buyer Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.
Buyer Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Omega-3 Acid Ethyl Esters
Omega-3 acid ethyl ester therapeutics that lower excessive triglyceride levels.
Buyer Products:
|
|
|
|
Porphyrias |
|
|
|
Acute Intermittent |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat porphyrias by blocking the receptor that binds the neurotransmitter, dopamine.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Omega-3 Acid Ethyl Esters
Omega-3 acid ethyl ester therapeutics that lower excessive triglyceride levels.
Buyer Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocytopenia |
|
|
|
Thrombopoietin Agonists
Therapeutics that treat thrombocytopenia by stimulating thrombopoietin, which promotes the production of platelets.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Idiopathic Thrombocytopenia Purpura (ITP) |
|
|
|
Thrombopoietin Agonists
Therapeutics that treat thrombocytopenia by stimulating thrombopoietin, which promotes the production of platelets.
Buyer Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Systemic (SLE) |
|
|
|
Monoclonal Antibodies
Therapeutics that treat systemic lupus by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that treat psoriasis by stimulating immune response and regulating inflammation and skin cell proliferation.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Penicillin Derivatives/Beta-Lactamase Inhibitors
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication and increasing susceptibility to penicillin derived compounds.
Buyer Products:
|
|
|
|
Pleuromutilins
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis through binding onto ribosome.
Buyer Products:
|
|
|
|
Pseudominic Acids
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and RNA synthesis.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Musculoskeletal System |
|
|
|
Bone/Joint Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat bacterial infections manifested in the bones or joints by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Meningitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lining of the brain and spinal cord by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Penicillin Derivatives/Beta-Lactamase Inhibitors
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting bacterial cell wall synthesis during active multiplication and increasing susceptibility to penicillin derived compounds.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Pharyngitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the cone shaped cavity at the back of the mouth caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat infections of the air passage caused by a wide variety of bacteria.
Buyer Products:
|
|
|
|
Tonsilitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lymphoid tissue on either side of the throat caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Combination |
|
|
|
Diphtheria/Tetanus/Acellular Pertussis (DTaP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and acellular pertussis.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Haemophilus Influenzae Type B (Hib)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause Haemophilus influenzae type B.
Buyer Products:
|
|
|
|
Meningitis
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause meningitis.
Buyer Products:
|
|
|
|
Streptococcus pneumoniae
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause pneumococcal bacteria.
Buyer Products:
|
|
|
|
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.
Buyer Products:
|
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.
Buyer Products:
|
|
|
|
Helminthic |
|
|
|
Hydatid Disease |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections characterized by formation of cysts in a several organs.
Buyer Products:
|
|
|
|
Neurocysticercosis |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections caused by a tapeworm in the brain.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Respiratory System |
|
|
|
Pneumocystis Carinii Pneumonia (PCP) |
|
|
|
Protozoan Metabolism Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by preventing metabolism and growth in organism.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
|
Toxoplasmosis (Toxo) |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat infections caused by Toxoplasma gondii and characterized by lesions in the heart, brain, and eye by preventing folic acid synthesis.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Hepadnavirus |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months by blocking enzyme essential for viral DNA synthesis.
Buyer Products:
|
|
|
|
Herpesvirus |
|
|
|
Herpes Labialis (Cold Sores) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Viral Fusion Inhibitors
Therapeutics that treat cold sores by inhibiting fusion of viral material into human cell plasma membranes.
Buyer Products:
|
|
|
|
Herpes Simplex Type 1 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|